\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ surgical\\ resection\ \(126\)\
\-\ the\\ immunostain\\ results\\ \\(positive\\ r132h\\ idh1\\ staining\\,\\ clonal\\ p53\\ positivity\\,\\ and\\ negative\\ egfr\\ expression\\)\\ are\\ consistent\\ with\\ the\\ diagnosis\\ of\\ a\\ diffuse\\ fibrillary\\ astrocytoma\\.\\ \\ \ \(0\)\
\-\ the\\ following\\ immunostain\\ results\\ were\\ obtained\\ on\\ b14\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\-\\ p53\\:\\ strong\\ clonal\\ staining\\ in\\ tumor\\ cells\\.\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\-\\ idh1\\ \\(r132h\\)\\:\\ strongly\\ positive\\ in\\ tumor\\ cells\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\-\\ egfr\\:\\ negative\\ in\\ tumor\\ cells\\.\ \(0\)\
\-\ on\\ the\\ basis\\ of\\ focal\\ increased\\ cellularity\\ and\\ atypia\\,\\ increased\\ mitotic\\ activity\\ \\(at\\ least\\ three\\ high\\-power\\-fields\\ containing\\ two\\ mitoses\\ each\\ are\\ noted\\)\\,\\ focal\\ perivascular\\ macrophages\\,\\ and\\ focal\\ minor\\/rudimentary\\ microvascular\\ proliferation\\,\\ it\\ is\\ felt\\ that\\ the\\ tumor\\ may\\ be\\ more\\ aggressive\ \(0\)\
\-\ than\\ is\\ usual\\ for\\ grade\\ 2\\ astrocytomas\\.\ \(1\)\
\-\ minimally\\ enhancing\\ mass\\ left\\ temporal\\ lobe\\.\ \(0\)\
\-\ moderate\\ amount\\ of\\ edema\\.\\ \\ no\\ hemorrhage\\.\ \(0\)\
\-\ diffuse\\ astrocytoma\\,\\ who\\ 2\\-3\\,\\ temporal\\ lobe\ \(0\)\
\-\ \\â\\€\\¢\\ herpes\\ encephalitis\ \(0\)\
\-\ \\â\\€\\¢\\ resolving\\ hematoma\ \(0\)\
\-\ \\â\\€\\¢\\ dnet\ \(0\)\
\-\ \\â\\€\\¢\\ infiltrating\\ glial\\ neoplasm\\ \\-\\ astrocytoma\\ vs\\.\\ oligodendrglioma\ \(0\)\
\-\ 23\\ year\\ old\\ man\\ presents\\ with\\ a\\ first\\ time\\ seizure\\.\\ no\\ fever\\.\ \(0\)\
\-\ 1st\\ mri\\ head\\:\\ \\"\\.\\.\\.\\.masslike\\ expansion\\ of\\ the\\ left\\ temporal\\ lobe\\ involving\\ primarily\\ the\\ medial\\ aspect\\ with\\ cortical\\ thickening\\ of\\ the\\ mesial\\ temporal\\ lobe\\ and\\ hippocampus\\ \\.\\ there\\ is\\ elevated\\ t2\\ hyperintense\\ signal\ \(0\)\
\-\ involving\\ the\\ temporal\\ lobe\\ extending\\ through\\ the\\ white\\ matter\\ tracts\\ cephalad\\ to\\ the\\ left\\ basal\\ ganglia\\ and\\ above\\ the\\ left\\ occipital\\ trigone\\ and\\ medial\\ aspect\\ of\\ the\\ left\\ occipital\\ lobe\\.\\ the\\ inferomedial\\ left\\ frontal\\ lobe\\ and\\ anterior\\ commissure\\ also\\ shows\\ t2\\ hyperintense\\ signal\\ and\\ there\\ is\ \(0\)\
\-\ cortical\\ thickening\\ of\\ the\\ left\\ frontal\\ lobe\\.\\ there\\ is\\ no\\ evidence\\ for\\ enhancement\\ within\\ this\\ region\\ although\\ a\\ number\\ of\\ enhancing\\ prominent\\ medullary\\ vessels\\ course\\ through\\ the\\ above\\ area\\.\\ \\.\\.\\.\\ findings\\ are\\ concerning\ \(0\)\
\-\ for\\ encephalitis\\ or\\ infiltrating\\ glioma\\.\\.\\.\\"\ \(1\)\
\-\ 2nd\\ mri\\ head\\ three\\ week\\ later\\:\\ \\"\\.\\.\\.impression\\:\\ 1\\.\\ study\\ obtained\\ for\\ stereotactic\\ localization\\ of\\ lesion\\ centered\\ within\\ the\\ left\\ temporal\\ lobe\\.\\ this\\ lesion\\ has\\ not\\ significantly\\ changed\\ since\\ the\\ prior\\ studies\\.\\ this\\ is\\ likely\\ a\\ glioma\\.\\"\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lobe\\:\\ 0\\.05980904084194164\ \(0\)\
\-\ temporal\\:\\ 0\\.059339148166719126\ \(0\)\
\-\ immunostain\\:\\ 0\\.04695012279425753\ \(0\)\
\-\ r132h\\:\\ 0\\.04695012279425753\ \(0\)\
\-\ clonal\\:\\ 0\\.04695012279425753\ \(0\)\
\-\ \\.\\.\\.\\:\\ 0\\.04694498013558678\ \(0\)\
\-\ idh1\\:\\ 0\\.04460639384565542\ \(0\)\
\-\ egfr\\:\\ 0\\.04460639384565542\ \(0\)\
\-\ p53\\:\\ 0\\.04294349169275496\ \(0\)\
\-\ staining\\:\\ 0\\.032832509873048255\ \(0\)\
\-\ cells\\:\\ 0\\.029709075382803443\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.028771822531849386\ \(0\)\
\-\ encephalitis\\:\\ 0\\.02758651535336386\ \(0\)\
\-\ infiltrating\\:\\ 0\\.026827347711392256\ \(0\)\
\-\ b14\\:\\ 0\\.025478376947880053\ \(0\)\
\-\ high\\-power\\-fields\\:\\ 0\\.025478376947880053\ \(0\)\
\-\ minor\\/rudimentary\\:\\ 0\\.025478376947880053\ \(0\)\
\-\ oligodendrglioma\\:\\ 0\\.025478376947880053\ \(0\)\
\-\ masslike\\:\\ 0\\.023475061397128766\ \(0\)\
\-\ occipital\\:\\ 0\\.02304742593447513\ \(0\)\
\-\ tumor\\:\\ 0\\.02303158730185909\ \(0\)\
\-\ \\:\\:\\ 0\\.022866831537383395\ \(0\)\
\-\ positivity\\:\\ 0\\.02230319692282771\ \(0\)\
\-\ commissure\\:\\ 0\\.02230319692282771\ \(0\)\
\-\ glioma\\:\\ 0\\.022269790715067\ \(0\)\
\-\ left\\:\\ 0\\.022106480214402653\ \(0\)\
\-\ hippocampus\\:\\ 0\\.02147174584637748\ \(0\)\
\-\ \\-\\:\\ 0\\.021176051545761427\ \(0\)\
\-\ focal\\:\\ 0\\.021160349168830073\ \(0\)\
\-\ fibrillary\\:\\ 0\\.02082682228766589\ \(0\)\
\-\ hyperintense\\:\\ 0\\.020506706733544336\ \(0\)\
\-\ mitoses\\:\\ 0\\.020299881372076424\ \(0\)\
\-\ results\\:\\ 0\\.019939551496789866\ \(0\)\
\-\ \\.\\.\\.\\.\\:\\ 0\\.019854359176043886\ \(0\)\
\-\ atypia\\:\\ 0\\.01946843029562619\ \(0\)\
\-\ mitotic\\:\\ 0\\.01946843029562619\ \(0\)\
\-\ inferomedial\\:\\ 0\\.01946843029562619\ \(0\)\
\-\ microvascular\\:\\ 0\\.01912801689777537\ \(0\)\
\-\ mesial\\:\\ 0\\.01912801689777537\ \(0\)\
\-\ expression\\:\\ 0\\.018823506736914603\ \(0\)\
\-\ cellularity\\:\\ 0\\.018823506736914603\ \(0\)\
\-\ glial\\:\\ 0\\.018823506736914603\ \(0\)\
\-\ trigone\\:\\ 0\\.018296565821325137\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.01811577285081951\ \(0\)\
\-\ above\\:\\ 0\\.018103691656808186\ \(0\)\
\-\ cortical\\:\\ 0\\.018006213009108738\ \(0\)\
\-\ macrophages\\:\\ 0\\.0178510436252926\ \(0\)\
\-\ obtained\\:\\ 0\\.017559919657478853\ \(0\)\
\-\ involving\\:\\ 0\\.017331833895972794\ \(0\)\
\-\ astrocytomas\\:\\ 0\\.017124701347024086\ \(0\)\
\-\ cephalad\\:\\ 0\\.017124701347024086\ \(0\)\
\-\ perivascular\\:\\ 0\\.016820191186163316\ \(0\)\
\-\ stereotactic\\:\\ 0\\.016820191186163316\ \(0\)\
\-\ thickening\\:\\ 0\\.016743494622504924\ \(0\)\
\-\ three\\:\\ 0\\.01665100710027116\ \(0\)\
\-\ tracts\\:\\ 0\\.01654472823875197\ \(0\)\
\-\ localization\\:\\ 0\\.016061912965159006\ \(0\)\
\-\ positive\\:\\ 0\\.01602824040626657\ \(0\)\
\-\ herpes\\:\\ 0\\.01595283687272303\ \(0\)\
\-\ medial\\:\\ 0\\.01579941915369972\ \(0\)\
\-\ changed\\:\\ 0\\.01564832671186226\ \(0\)\
\-\ aspect\\:\\ 0\\.015516138349614782\ \(0\)\
\-\ frontal\\:\\ 0\\.015516138349614782\ \(0\)\
\-\ enhancing\\:\\ 0\\.015491060883726931\ \(0\)\
\-\ resolving\\:\\ 0\\.015461799194123617\ \(0\)\
\-\ dnet\\:\\ 0\\.015461799194123617\ \(0\)\
\-\ diffuse\\:\\ 0\\.014953800117776386\ \(0\)\
\-\ proliferation\\:\\ 0\\.014890048490857953\ \(0\)\
\-\ basis\\:\\ 0\\.014816875635412027\ \(0\)\
\-\ negative\\:\\ 0\\.014752139661126441\ \(0\)\
\-\ 1st\\:\\ 0\\.014541412688000684\ \(0\)\
\-\ centered\\:\\ 0\\.01447646223756121\ \(0\)\
\-\ usual\\:\\ 0\\.01441293938577284\ \(0\)\
\-\ strong\\:\\ 0\\.014350782723284508\ \(0\)\
\-\ through\\:\\ 0\\.01402865328566976\ \(0\)\
\-\ head\\:\\ 0\\.014009256130484947\ \(0\)\
\-\ t2\\:\\ 0\\.01398028190029105\ \(0\)\
\-\ strongly\\:\\ 0\\.013742992524335489\ \(0\)\
\-\ 2\\-3\\:\\ 0\\.013326086140391711\ \(0\)\
\-\ impression\\:\\ 0\\.013199488965078436\ \(0\)\
\-\ signal\\:\\ 0\\.013023551042039182\ \(0\)\
\-\ primarily\\:\\ 0\\.012961806600231697\ \(0\)\
\-\ concerning\\:\\ 0\\.012961806600231697\ \(0\)\
\-\ minimally\\:\\ 0\\.01284991494653028\ \(0\)\
\-\ each\\:\\ 0\\.01277765684767069\ \(0\)\
\-\ ganglia\\:\\ 0\\.012638344414671045\ \(0\)\
\-\ significantly\\:\\ 0\\.012638344414671045\ \(0\)\
\-\ containing\\:\\ 0\\.012538097137249397\ \(0\)\
\-\ least\\:\\ 0\\.012378378412755034\ \(0\)\
\-\ number\\:\\ 0\\.012316883041520107\ \(0\)\
\-\ 2nd\\:\\ 0\\.012316883041520107\ \(0\)\
\-\ expansion\\:\\ 0\\.01216863652594915\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.012139508888045185\ \(0\)\
\-\ increased\\:\\ 0\\.012083727062425755\ \(0\)\
\-\ aggressive\\:\\ 0\\.012083206461667231\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.01190606648544649\ \(0\)\
\-\ medullary\\:\\ 0\\.011867017984549607\ \(0\)\
\-\ 23\\:\\ 0\\.011739676973584202\ \(0\)\
\-\ felt\\:\\ 0\\.011617710631126465\ \(0\)\
\-\ mri\\:\\ 0\\.011348415346327282\ \(0\)\
\-\ basal\\:\\ 0\\.01125877889635368\ \(0\)\
\-\ there\\:\\ 0\\.011026435460679091\ \(0\)\
\-\ seizure\\:\\ 0\\.010920710466915807\ \(0\)\
\-\ amount\\:\\ 0\\.01031356749076882\ \(0\)\
\-\ prominent\\:\\ 0\\.010136562793541309\ \(0\)\
\-\ are\\:\\ 0\\.010100062478580361\ \(0\)\
\-\ lesion\\:\\ 0\\.010061012867054651\ \(0\)\
\-\ vessels\\:\\ 0\\.00994289022046917\ \(0\)\
\-\ is\\:\\ 0\\.009750707139619518\ \(0\)\
\-\ vs\\:\\ 0\\.009723930550291322\ \(0\)\
\-\ matter\\:\\ 0\\.009723930550291322\ \(0\)\
\-\ moderate\\:\\ 0\\.009711552915054326\ \(0\)\
\-\ within\\:\\ 0\\.00942272490396579\ \(0\)\
\-\ grade\\:\\ 0\\.009407042754193556\ \(0\)\
\-\ course\\:\\ 0\\.009319455038889136\ \(0\)\
\-\ activity\\:\\ 0\\.009266030719021788\ \(0\)\
\-\ studies\\:\\ 0\\.009223991091847282\ \(0\)\
\-\ non\\-contributory\\:\\ 0\\.009121491931233747\ \(0\)\
\-\ since\\:\\ 0\\.009071574051150914\ \(0\)\
\-\ later\\:\\ 0\\.00891739491616452\ \(0\)\
\-\ hematoma\\:\\ 0\\.008788921613936676\ \(0\)\
\-\ for\\:\\ 0\\.008428995938066071\ \(0\)\
\-\ neoplasm\\:\\ 0\\.00841085715581482\ \(0\)\
\-\ week\\:\\ 0\\.008387327798636497\ \(0\)\
\-\ elevated\\:\\ 0\\.008379527055951049\ \(0\)\
\-\ fever\\:\\ 0\\.008356250365757127\ \(0\)\
\-\ although\\:\\ 0\\.008340836071030646\ \(0\)\
\-\ this\\:\\ 0\\.008333559653012714\ \(0\)\
\-\ extending\\:\\ 0\\.008302656210519644\ \(0\)\
\-\ first\\:\\ 0\\.008287524377993792\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.00822039475195386\ \(0\)\
\-\ white\\:\\ 0\\.008191052637896004\ \(0\)\
\-\ study\\:\\ 0\\.008126102187456529\ \(0\)\
\-\ area\\:\\ 0\\.007808775272064356\ \(0\)\
\-\ 1\\.\\:\\ 0\\.007714419555773413\ \(0\)\
\-\ resection\\:\\ 0\\.007702068368555545\ \(0\)\
\-\ no\\:\\ 0\\.0074604984165069525\ \(0\)\
\-\ the\\:\\ 0\\.007192159319841805\ \(0\)\
\-\ two\\:\\ 0\\.007073211669410421\ \(0\)\
\-\ following\\:\\ 0\\.007009473285841469\ \(0\)\
\-\ edema\\:\\ 0\\.006985328004136678\ \(0\)\
\-\ time\\:\\ 0\\.00697572609028703\ \(0\)\
\-\ region\\:\\ 0\\.00697572609028703\ \(0\)\
\-\ likely\\:\\ 0\\.006966155970912302\ \(0\)\
\-\ shows\\:\\ 0\\.006790097398060343\ \(0\)\
\-\ enhancement\\:\\ 0\\.006619909728679294\ \(0\)\
\-\ evidence\\:\\ 0\\.006475267581985195\ \(0\)\
\-\ than\\:\\ 0\\.006471239465081716\ \(0\)\
\-\ who\\:\\ 0\\.006439215055322838\ \(0\)\
\-\ anterior\\:\\ 0\\.0063606729010483734\ \(0\)\
\-\ prior\\:\\ 0\\.006341366393648449\ \(0\)\
\-\ \\(\\:\\ 0\\.006263251961651969\ \(0\)\
\-\ \\,\\:\\ 0\\.006259192266295662\ \(0\)\
\-\ \\)\\:\\ 0\\.006186742995202067\ \(0\)\
\-\ more\\:\\ 0\\.006176810142520712\ \(0\)\
\-\ consistent\\:\\ 0\\.006055775343442783\ \(0\)\
\-\ noted\\:\\ 0\\.00585381846373582\ \(0\)\
\-\ man\\:\\ 0\\.005840843477138725\ \(0\)\
\-\ diagnosis\\:\\ 0\\.005671154135203526\ \(0\)\
\-\ were\\:\\ 0\\.0056077639788726045\ \(0\)\
\-\ it\\:\\ 0\\.005551584926396002\ \(0\)\
\-\ may\\:\\ 0\\.0054171340141564266\ \(0\)\
\-\ 2\\:\\ 0\\.005318221088180769\ \(0\)\
\-\ findings\\:\\ 0\\.005256754149681964\ \(0\)\
\-\ surgical\\:\\ 0\\.005191392399570675\ \(0\)\
\-\ presents\\:\\ 0\\.00504521472690152\ \(0\)\
\-\ also\\:\\ 0\\.0048688427562721135\ \(0\)\
\-\ has\\:\\ 0\\.004637861186399647\ \(0\)\
\-\ a\\:\\ 0\\.004584968807151459\ \(0\)\
\-\ that\\:\\ 0\\.004265840255950356\ \(0\)\
\-\ on\\:\\ 0\\.004184341111938891\ \(0\)\
\-\ and\\:\\ 0\\.004162057936005051\ \(0\)\
\-\ be\\:\\ 0\\.0038085454431905463\ \(0\)\
\-\ in\\:\\ 0\\.0036537332093085685\ \(0\)\
\-\ not\\:\\ 0\\.0035688400917396976\ \(0\)\
\-\ mass\\:\\ 0\\.003434858401582556\ \(0\)\
\-\ at\\:\\ 0\\.003346136279860211\ \(0\)\
\-\ of\\:\\ 0\\.003030445685496809\ \(0\)\
\-\ or\\:\\ 0\\.0028945744189702526\ \(0\)\
\-\ year\\:\\ 0\\.0027633100268003316\ \(0\)\
\-\ old\\:\\ 0\\.0025287127076943773\ \(0\)\
\-\ \\.\\:\\ 0\\.0017441968602742392\ \(0\)\
\-\ to\\:\\ 0\\.0012343008914537175\ \(0\)\
\-\ with\\:\\ 0\\.0010144870759238994\ \(0\)\
